Literature DB >> 31502025

Long-Term Mortality of Matched Patients with Intermittent Claudication Treated by High-Dose Paclitaxel-Coated Balloon Versus Plain Balloon Angioplasty: A Real-World Study.

Konstantinos P Donas1, Anne Sohr2, Georgios A Pitoulias3, Fernando Alfonso4, Giovanni Torsello2.   

Abstract

PURPOSE: The aim of this study was to assess the long-term mortality of patients treated by the IN.PACT Admiral (Medtronic, Dublin, Ireland) paclitaxel-coated balloon angioplasty (PCBA) compared with standard plain balloon angioplasty (POBA).
MATERIALS AND METHODS: Between January 2013 and January 2014, 238 patients met the inclusion criteria. A two-step analysis was performed. In step 1, the 5-year mortality of the whole patient population was evaluated regardless of possible differences in the patient demographics. In step 2, a matched paired analysis was performed using propensity scores. In addition, for those patients who were treated with PCBA, a possible correlation between dose of paclitaxel and mortality was evaluated.
RESULTS: Univariate analysis for the whole group of patients (POBA group A, n = 84 and PCBA group B, n = 121) showed a 5-year mortality rate of 26.2% versus 14.0%, p = 0.02, respectively. Univariate analysis of 77 pairs of propensity score-matched patients resulted in mortality of 26.0% versus 20.8%, p = 0.4, of group A and B, respectively (median follow-up of 61.7 and 61.8 months, p = 0.8, respectively). Comparison of the patients of group B who died versus those who survived showed no correlation between the dose of paclitaxel with increased mortality (p = 0.4).
CONCLUSION: The 5-year findings of the present real-world study showed no increased mortality for the matched patients who underwent PCBA versus POBA. In addition, there was no correlation between mortality and the dose of paclitaxel used.

Entities:  

Keywords:  Drug coated balloon angioplasty; Mortality; Plain balloon angioplasty; Real-world study

Mesh:

Substances:

Year:  2019        PMID: 31502025     DOI: 10.1007/s00270-019-02329-z

Source DB:  PubMed          Journal:  Cardiovasc Intervent Radiol        ISSN: 0174-1551            Impact factor:   2.740


  4 in total

Review 1.  Update on paclitaxel for femoral-popliteal occlusive disease in the 15 months following a summary level meta-analysis demonstrated increased risk of late mortality and dose response to paclitaxel.

Authors:  Peter A Schneider; Ramon L Varcoe; Eric Secemsky; Marc Schermerhorn; Andrew Holden
Journal:  J Vasc Surg       Date:  2020-09-02       Impact factor: 4.268

2.  COMPARE: prospective, randomized, non-inferiority trial of high- vs. low-dose paclitaxel drug-coated balloons for femoropopliteal interventions.

Authors:  Sabine Steiner; Andrej Schmidt; Thomas Zeller; Gunnar Tepe; Marcus Thieme; Lars Maiwald; Henrik Schröder; Wulf Euringer; Matthias Ulrich; Klaus Brechtel; Steffen Brucks; Erwin Blessing; Johannes Schuster; Ralf Langhoff; Sebastian Schellong; Norbert Weiss; Dierk Scheinert
Journal:  Eur Heart J       Date:  2020-07-14       Impact factor: 29.983

3.  Long-Term Outcomes of the 150 mm Drug-Coated Balloon Cohort from the IN.PACT Global Study.

Authors:  Marianne Brodmann; Wouter Lansink; Katharina Guetl; Antonio Micari; Jeremiah Menk; Thomas Zeller
Journal:  Cardiovasc Intervent Radiol       Date:  2022-07-21       Impact factor: 2.797

4.  Paclitaxel exposure: Long-term safety and effectiveness of a drug-coated balloon for claudication in pooled randomized trials.

Authors:  Peter A Schneider; Marianne Brodmann; Laura Mauri; John Laird; Yoshimitsu Soga; Antonio Micari; Gary Ansel; Mehdi H Shishehbor; Prakash Krishnan; Qi Gao; Kenneth Ouriel; Thomas Zeller
Journal:  Catheter Cardiovasc Interv       Date:  2020-08-24       Impact factor: 2.692

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.